ICU Medical, Inc. (ICUI)
ICUI Stock Price Chart
Explore ICU Medical, Inc. interactive price chart. Choose custom timeframes to analyze ICUI price movements and trends.
ICUI Company Profile
Discover essential business fundamentals and corporate details for ICU Medical, Inc. (ICUI) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Instruments & Supplies
IPO Date
31 Mar 1992
Employees
15.00K
Website
https://www.icumed.comCEO
Vivek Jain
Description
ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy and critical care applications worldwide. The company's infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; SwabCap and SwabTip disinfecting caps; Tego hemodialysis connectors; ClearGuard HD, an antimicrobial barrier cap for hemodialysis catheters; and ChemoClave and ChemoLock closed system transfer devices, as well as Diana hazardous drug compounding system for the preparation of hazardous drugs. It also provides IV therapy and diluents, such as sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation comprising sodium chloride and sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. The company offers infusion pumps under the Plum 360 and LifeCare PCA brands; IV mediation safety software, including ICU Medical MedNet, an enterprise-class medication management platform that connects smart pumps to hospital's electronic health records, asset tracking systems, and alarm notification platforms; and related professional services. It also provides critical care products, such as Cogent 2-in-1 and CardioFlo hemodynamic monitoring systems; TDQ and OptiQ cardiac output monitoring catheters; TriOx venous oximetry catheters; Transpac blood pressure transducers; and SafeSet closed blood sampling and conservation systems. The company sells its products to acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, including outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is headquartered in San Clemente, California.
ICUI Financial Timeline
Browse a chronological timeline of ICU Medical, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 May 2026
Upcoming earnings on 25 Feb 2026
Upcoming earnings on 11 Nov 2025
EPS estimate is $1.54.
Earnings released on 7 Aug 2025
EPS came in at $2.10 surpassing the estimated $1.44 by +45.83%, while revenue for the quarter reached $548.87M , beating expectations by +7.31%.
Earnings released on 8 May 2025
EPS came in at $1.72 surpassing the estimated $1.23 by +39.84%, while revenue for the quarter reached $604.70M , beating expectations by +0.17%.
Earnings released on 27 Feb 2025
EPS came in at $2.11 surpassing the estimated $1.48 by +42.57%, while revenue for the quarter reached $629.81M , beating expectations by +5.13%.
Earnings released on 12 Nov 2024
EPS came in at $1.59 surpassing the estimated $1.25 by +27.20%, while revenue for the quarter reached $589.13M , beating expectations by +2.53%.
Earnings released on 7 Aug 2024
EPS came in at $1.56 surpassing the estimated $0.98 by +59.18%, while revenue for the quarter reached $596.46M , beating expectations by +7.72%.
Earnings released on 7 May 2024
EPS came in at $0.96 surpassing the estimated $0.84 by +14.29%, while revenue for the quarter reached $565.96M , beating expectations by +2.48%.
Earnings released on 27 Feb 2024
EPS came in at $1.57 surpassing the estimated $1.18 by +33.05%, while revenue for the quarter reached $587.99M , beating expectations by +4.43%.
Earnings released on 6 Nov 2023
EPS came in at $1.57 surpassing the estimated $1.29 by +21.71%, while revenue for the quarter reached $553.31M , missing expectations by -1.69%.
Earnings released on 7 Aug 2023
EPS came in at $1.88 surpassing the estimated $1.55 by +21.29%, while revenue for the quarter reached $549.31M , missing expectations by -3.38%.
Earnings released on 8 May 2023
EPS came in at $1.74 surpassing the estimated $1.38 by +26.09%, while revenue for the quarter reached $568.65M , beating expectations by +0.59%.
Earnings released on 27 Feb 2023
EPS came in at $1.60 surpassing the estimated $1.50 by +6.67%, while revenue for the quarter reached $578.01M , missing expectations by -0.13%.
Earnings released on 7 Nov 2022
EPS came in at $1.75 surpassing the estimated $1.41 by +24.11%, while revenue for the quarter reached $597.86M , beating expectations by +5.82%.
Earnings released on 8 Aug 2022
EPS came in at $1.37 falling short of the estimated $1.69 by -18.93%, while revenue for the quarter reached $561.00M , beating expectations by +0.19%.
Earnings released on 9 May 2022
EPS came in at $1.82 surpassing the estimated $1.79 by +1.68%, while revenue for the quarter reached $543.12M , missing expectations by -1.82%.
Earnings released on 24 Feb 2022
EPS came in at $1.82 surpassing the estimated $1.63 by +11.66%, while revenue for the quarter reached $340.53M , beating expectations by +6.45%.
Earnings released on 3 Nov 2021
EPS came in at $2.07 surpassing the estimated $1.79 by +15.64%, while revenue for the quarter reached $336.06M , beating expectations by +6.92%.
Earnings released on 4 Aug 2021
EPS came in at $1.88 surpassing the estimated $1.64 by +14.63%, while revenue for the quarter reached $321.68M , beating expectations by +3.33%.
Earnings released on 6 May 2021
EPS came in at $1.62 surpassing the estimated $1.53 by +5.88%, while revenue for the quarter reached $318.05M , beating expectations by +5.70%.
Earnings released on 25 Feb 2021
EPS came in at $1.77 surpassing the estimated $1.48 by +19.59%, while revenue for the quarter reached $320.45M , beating expectations by +8.51%.
Earnings released on 5 Nov 2020
EPS came in at $1.90 surpassing the estimated $1.28 by +48.44%, while revenue for the quarter reached $318.57M , beating expectations by +45.04%.
ICUI Stock Performance
Access detailed ICUI performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.